The Use of the Hormone Kisspeptin in 'in Vitro Fertilisation' (IVF) Treatment

• Status: Completed
• Trial end date: 2016-10-11
• Target enrollment: 0
• Participant gender: Female

Summary

We want to find out if kisspeptin is successful in stimulating oocyte maturation when it is used as a 'trigger' injection during IVF therapy for infertility.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Imperial College London
• Treatments: Hormones

Criteria

Inclusion Criteria:

• Aged 18 - 34 years

• Body mass index between 18 and 29 kg/m2

• Stable body weight for at least 3 months

• Normal early menstrual cycle follicular phase serum FSH concentration

• Serum anti-Mullerian hormone (AMH) > 40pmol/L

• No more than one previous IVF treatment cycle

• Both ovaries intact

Exclusion Criteria:

History of any medical, psychological or other condition, or use of any medications, including over-the-counter products, which, in the opinion of the investigators, would either interfere with the study or potentially cause harm to the volunteer

• Without access at home to a telephone, or other factor likely to interfere with ability to participate reliably in the study

• Treatment with an investigational drug within the preceding 2 months

• Donated blood during the preceding 3 months or intention to do so before the end of the study

• Previous poor response to IVF treatment